RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+15.06%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$1B
AUM Growth
+$1B
(+7.9%)
Cap. Flow
-$30M
Cap. Flow
% of AUM
-3%
Top 10 Holdings %
Top 10 Hldgs %
34.85%
Holding
100
New
15
Increased
28
Reduced
32
Closed
15
Top Buys
| 1 |
Medtronic
MDT
|
$17.8M |
| 2 |
Thermo Fisher Scientific
TMO
|
$17.5M |
| 3 |
Pfizer
PFE
|
$16.7M |
| 4 |
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
|
$11.2M |
| 5 |
DexCom
DXCM
|
$8.07M |
Top Sells
| 1 |
Becton Dickinson
BDX
|
$24.6M |
| 2 |
CVS Health
CVS
|
$12.8M |
| 3 |
Eli Lilly
LLY
|
$12.8M |
| 4 |
Elevance Health
ELV
|
$11.8M |
| 5 |
McKesson
MCK
|
$11.6M |
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Medtronic
MDT
$119B
| $48.7M | 4.86% | 591,000 +216,000 | +58% | +$17.8M |
|
|
2
Eli Lilly
LLY
$657B
| $45.5M | 4.54% | 78,005 -21,995 | -22% | -$12.8M |
|
3
Boston Scientific
BSX
$156B
| $43.4M | 4.33% | 750,000 +50,000 | +7% | +$2.89M |
|
4
Vertex Pharmaceuticals
VRTX
$100B
| $38.7M | 3.86% | 95,000 +18,500 | +24% | +$7.53M |
|
5
Regeneron Pharmaceuticals
REGN
$61.5B
| $34.3M | 3.42% | 39,000 -1,000 | -3% | -$878K |
|
6
HCA Healthcare
HCA
$94.5B
| $29.5M | 2.95% | 109,000 +26,000 | +31% | +$7.04M |
|
7
UnitedHealth
UNH
$281B
| $28.4M | 2.84% | 54,000 +8,000 | +17% | +$4.21M |
|
8
BioMarin Pharmaceuticals
BMRN
$11.2B
| $27.2M | 2.72% | 282,500 -97,500 | -26% | -$9.4M |
|
|
SWAV
9
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
| $26.7M | 2.67% | 140,000 +59,000 | +73% | +$11.2M |
|
10
Tenet Healthcare
THC
$16.3B
| $26.6M | 2.65% | 351,630 +16,630 | +5% | +$1.26M |
|
11
AbbVie
ABBV
$372B
| $25.9M | 2.59% | 167,000 +17,000 | +11% | +$2.63M |
|
12
Abbott
ABT
$231B
| $22.6M | 2.25% | 205,000 -56,675 | -22% | -$6.24M |
|
13
Cooper Companies
COO
$13.4B
| $22.1M | 2.21% | 58,500 -1,500 | -3% | -$568K |
|
14
Intuitive Surgical
ISRG
$170B
| $21.4M | 2.14% | 63,500 -4,000 | -6% | -$1.35M |
|
|
15
McKesson
MCK
$85.4B
| $21.3M | 2.13% | 46,000 -25,000 | -35% | -$11.6M |
|
16
Gilead Sciences
GILD
$140B
| $21M | 2.1% | 259,000 +25,000 | +11% | +$2.03M |
|
17
Cencora
COR
$56.5B
| $19.7M | 1.97% | 96,000 -23,000 | -19% | -$4.72M |
|
18
Danaher
DHR
$147B
| $18M | 1.8% | 78,000 +18,000 | +30% | +$4.16M |
|
19
Humana
HUM
$36.5B
| $17.9M | 1.79% | 39,083 -9,917 | -20% | -$4.54M |
|
|
20
Thermo Fisher Scientific
TMO
$186B
| $17.8M | 1.78% | 33,500 +33,000 | +6,600% | +$17.5M |
|
|
21
Pfizer
PFE
$141B
| $16.7M | 1.67% | +580,000 | New | +$16.7M |
|
22
Merck
MRK
$210B
| $16.1M | 1.61% | 147,500 -42,500 | -22% | -$4.63M |
|
23
Natera
NTRA
$23.1B
| $15.3M | 1.53% | 245,000 -21,769 | -8% | -$1.36M |
|
24
Jazz Pharmaceuticals
JAZZ
$7.75B
| $15.2M | 1.52% | 123,634 -20,000 | -14% | -$2.46M |
|
25
Biogen
BIIB
$19.4B
| $15.2M | 1.52% | 58,672 +2,172 | +4% | +$562K |
|